A real‐world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672)

AIM: This is a pre‐post observational study from an endocrinology ambulatory care practice which assessed the effectiveness and safety following the addition of a glucagon‐like peptide‐1 (GLP‐1) agonist, weekly exenatide (Bydureon), to basal insulin therapy in patients with type 2 diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autores principales: Stryker, Matthew D., Kane, Michael P., Busch, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360919/
https://www.ncbi.nlm.nih.gov/pubmed/30815541
http://dx.doi.org/10.1002/edm2.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360919/
https://www.ncbi.nlm.nih.gov/pubmed/30815541
http://dx.doi.org/10.1002/edm2.4

Ejemplares similares